MariMed (MRMD) director Edward Gildea awarded 247,385 RSUs in lieu of cash fees

Rhea-AI Filing Summary

MariMed Inc. director equity compensation update: Director Edward Gildea reported receiving 247,385 restricted stock units (RSUs) of MariMed Inc. common stock on December 5, 2025. These RSUs convert to common shares on a one-for-one basis and are scheduled to vest in full on December 15, 2025 under the terms of his award agreement with the company. The filing states that the RSUs were granted in lieu of cash for a portion of his fees for serving on the Board of Directors. Following this grant, Gildea is shown as beneficially owning 657,823 shares of MariMed common stock directly, and 247,385 derivative securities in the form of RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gildea Edward J

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock								657,823	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/05/2025		A		247,385		(2)	(2)	Common Stock, par value $.001 per share	247,385	$0	247,385	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs vest in full on December 15, 2025, in accordance with the terms of the award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.

	/s/ Edward Gildea	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MariMed Inc. (MRMD) disclose in this Form 4 filing?

MariMed Inc. disclosed that director Edward Gildea received a grant of 247,385 restricted stock units (RSUs) on December 5, 2025, as part of his compensation for Board service.

How many restricted stock units did MariMed director Edward Gildea receive?

Edward Gildea received 247,385 RSUs, each of which will convert into one share of MariMed common stock, par value $0.001 per share.

When do Edward Gildea’s RSUs from MariMed (MRMD) vest?

The filing states that the 247,385 RSUs granted to Edward Gildea vest in full on December 15, 2025, according to his award agreement with MariMed.

Why were these RSUs granted to the MariMed director instead of cash?

The RSUs were granted in lieu of cash as payment for a portion of Edward Gildea’s fees for serving on MariMed’s Board of Directors.

How many MariMed shares does Edward Gildea beneficially own after this transaction?

After the reported transaction, Edward Gildea beneficially owns 657,823 shares of MariMed common stock directly and 247,385 derivative securities in the form of RSUs.

What is the exercise or purchase price of the RSUs granted to the MariMed director?

The Form 4 lists the price of the RSUs as $0, reflecting that they were granted as part of director compensation rather than purchased for cash.